Edgewise Therapeutics Inc Dossier - Source-backed chat

Edgewise Therapeutics Inc

EWTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.54

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $40.48Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $4.4B

Shares Outstanding 110.3M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Edgewise Therapeutics is a clinical-stage biopharmaceutical company that has transitioned into a pure-play cardiovascular specialist following the successful sale of its muscular dystrophy business (including sevasemten) to Servier in July 2026 for $1.55 billion upfront. This transformative transaction significantly de-risks the company's investment narrative by providing massive non-dilutive funding to accelerate its lead cardiovascular candidate, EDG-7500, which is entering Phase 3 development for hypertrophic cardiomyopathy (HCM) in Q4 2026. Backed by a robust balance sheet with pro forma cash and cash equivalents of approximately $1.53 billion, Edgewise is fully funded to advance its cardiovascular pipeline through potential regulatory approvals without the need for dilutive equity financing.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$36.00

Mean target$51.15

High · most bullish analyst$66.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$25.0020%

The bear case is defined by clinical trial failures or safety concerns. If the Phase 3 trial for EDG-7500 fails to show statistically significant efficacy or if long-term safety issues emerge (such as reductions in LVEF below 50%), the company's valuation would contract sharply. Additionally, competitive pressure from established cardiac myosin inhibitors (such as Camzyos or aficamten) would severely limit the company's long-term growth prospects and accelerate cash burn, especially now that Edgewise is a single-asset focused cardiovascular company following the divestiture of its muscular dystrophy business to Servier.

Base CaseCentral scenario

$51.1550%

Matches the consensus mean

The base case assumes that EDG-7500 successfully transitions into Phase 3 development for both obstructive and non-obstructive HCM in Q4 2026 following constructive regulatory feedback. The company's cash reserves, significantly bolstered by the $1.55 billion upfront cash from the completed Servier transaction, remain sufficient to fully fund EDG-7500 through potential approval without immediate highly dilutive financing, maintaining steady upward momentum in the stock price.

Bull CaseUpside scenario

$59.0030%

The bull case hinges on the flawless execution of Edgewise's cardiovascular pipeline. Following the successful divestiture of its muscular dystrophy business to Servier for $1.55 billion upfront, Edgewise is fully funded to advance its lead candidate, EDG-7500. If the upcoming Phase 3 trial for EDG-7500 in hypertrophic cardiomyopathy (HCM), targeted to initiate in Q4 2026, delivers positive pivotal data, it would establish Edgewise as a formidable competitor to established therapies and drive substantial valuation upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated clinical profile for EDG-7500, which improves diastolic function and ventricular relaxation without causing meaningful reductions in left ventricular ejection fraction (LVEF), potentially eliminating the need for intensive echocardiographic monitoring.
Strongly capitalized balance sheet with $1.55 billion in upfront cash from the Servier transaction, fully funding the development of the clinical cardiovascular pipeline including EDG-7500 through potential approval.
Strong balance sheet with approximately $560 million in cash, cash equivalents, and marketable securities, providing a solid runway into late 2027 to fund pivotal clinical milestones.

Key Investment Risks

High clinical development risk inherent to pre-revenue biotechnology companies, with valuation heavily dependent on upcoming binary trial readouts.
Intense competition in the hypertrophic cardiomyopathy space from large-cap pharmaceutical companies and established therapies like Bristol Myers Squibb's Camzyos and Cytokinetics' aficamten.
Long-term funding requirements, as transitioning multiple programs into Phase 3 development will significantly increase operating expenses and eventually require additional capital raises.

Thesis Invalidation Triggers

Failure of the Phase 3 trial for EDG-7500 in hypertrophic cardiomyopathy (HCM) to meet its primary efficacy endpoints.
Unexpected safety signals, such as clinically significant reductions in LVEF or other adverse events, in ongoing or future trials of EDG-7500.
Regulatory roadblocks or unfavorable feedback from the FDA during the end-of-phase-2 meeting for EDG-7500, delaying the initiation of Phase 3 development.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.